Loading...
A Paradigm Shift in Cancer Nanomedicine: From Traditional Tumor Targeting to Leveraging the Immune System
Twenty-five years after the approval of the first anticancer nanodrug, we have to start re(de)fining tumor-targeted drug delivery alongside advances in immuno-oncology. Because cancer is characterized by an immunological imbalance that goes beyond the primary tumor, we should focus on targeting, eng...
Saved in:
| Published in: | Drug Discov Today |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2021
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7611945/ https://ncbi.nlm.nih.gov/pubmed/33617793 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.drudis.2021.02.017 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|